Please login to the form below
gene-editing
This page shows the latest gene-editing news and features for those working in and with pharma, biotech and healthcare.
Duchenne UK backs Evox dystrophin delivery project
as well as experimental gene therapies that try to deliver a working dystrophin gene that are in clinical trials and gene-editing approaches such as CRISP/Cas9 that attempt to correct ... existing antibodies primed to respond to the viruses used to
Latest news
-
FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy
Trial could begin by year end. The FDA has lifted the clinical hold on the trial of a CRISPR gene-editing therapy CTX001 in patients with of sickle cell disease (SCD), ... CTX001 is an investigational, autologous, gene-edited haematopoietic stem cell
-
Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts
Isolated at a manufacturing facility, these cells are also engineered to allow CARs to recognise and destroy cancer cells, but are further modified using gene editing to limit an autoimmune response, ... Pfizer also has a 25% stake in the company,
-
Sangamo’s first gene-editing trial doesn’t convince investors
Sangamo’ s first gene-editing trial doesn’ t convince investors. Market spooked by inconclusive early results. ... gene-editing technology that is designed to modify liver cells to express the iduronate-2-sulfatase or IDS enzyme that is deficient in
-
Sanofi gets EU OK for Ablynx flagship drug Cablivi
of Bioverativ earlier this year which added two marketed haemophilia drugs as well as a pipeline of blood disorder products including genome editing drugs and gene therapies.
-
Allergan builds on gene editing deal
Allergan builds on gene editing deal. Irish firm will co-develop CRISPR candidate for vision-threatening disorder. ... genes. The approach has been making the rounds quite recently in the pharma space, but this ground-breaking gene therapy is struggling
More from news
Approximately 2 fully matching, plus 26 partially matching documents found.
Latest Intelligence
-
Bluebird Bio: on the cusp of a gene therapy revolution
That means gene products hitting that Glybera price of $1m are, for now at least, unlikely. ... CRISPR Therapeutics, one of the companies working with the exciting cutting-edge CRISPR/Cas9 gene editing technology, is looking to begin a phase I trial with
-
30 women leaders in UK healthcare (part 3)
23. Dr Kathy Niakan, Developmental Biologist, The Francis Crick Institute. The last few years have seen a huge surge of interest in new gene editing tools that have enormous potential as ... The greatest excitement is reserved for CRISPR-Cas9 gene editing
-
Gene therapy
the promise of gene therapy in the early nineties could not be remotely met. ... From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty transposases, CRISPR-Cas9 gene editing, ARCUS gene editing, nucleic acid vaccines,
-
Deal Watch March 2017
Editas Medicine has entered a strategic R&D alliance where Allergan has exclusive access to Editas’s CRISPR genome-editing programmes in ocular health, as well as options to license up ... 100. Editas. Allergan. R&D alliance. LCA10 and up to four other
-
Winning the war against cancer
areas such as the gene-editing CRISPR technology.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Eric Rhodes becomes CEO of ERS Genomics
In these roles, Rhodes was responsible for commercialising the company's genome editing technologies as well as driving its research and development. ... Biosciences. Foy said: “ With his deep understanding of the gene-editing landscape and extensive
-
Marc Becker joins CRISPR Therapeutics
Marc Becker joins CRISPR Therapeutics. He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Consumption of Synthetic Biology Market to Remain High During 2026
In past few years synthetic biology has gained industrial interest which has a large scale applications and potential of new gene editing techniques are some of the drivers for this market.
-
Random42 Partner with MedCity for BioJapan 2018
J. Leading UK health scientists, universities and national research institutions will provide insight into the UK life sciences sector, and their work in ageing, gene editing and artificial intelligence.
-
Training the next generation of biotech leaders
Training the next generation of biotech leaders. Cell and gene therapy is no longer science fiction. ... It’ s such a disruptive advancement – it’ s just incredible to think it has all been made feasible through advancements in gene editing.”.
-
Perspective on biotech
Find out about:. The emerging technologies revolutionising the biotech industry – from immunotherapy breakthroughs to cutting-edge gene editing techniques.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Competitive Salary
- Digital Manager, London – Healthcare Brandcomms, Medcomms, PR
-
Excellent package
-
Medical/ Scientific Director
-
Salary TBC
-
Account Manager / Account Director
-
Competative
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
-
New Business Director - PR
-
Competitive Salary and benefits
- Senior Systematic Review Analyst - Oxford
-
Negotiable
-
Associate Medical Director
-
Highly Competitive
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Senior Medical Writer
-
Great salary and benefits
- Events Manager – Med Comms – Surrey
-
Salary TBC
-
Medical Writers
-
Competitive Salary and Benefits
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
- Senior Account Executive, London, Medical Communications
-
Excellent package
- Director, Market Access / HEOR - North-West
-
Negotiable
Subscribe to our email news alerts
- Chronic Lymphocytic Leukemia Market Professional Survey Report 2016-2026
- Pharmerging Contract Manufacturing Market Poised to Expand at a Robust Pace Over 2016-2026
- Donor Egg IVF Market Healthy Pace throughout the Forecast during 2016-2026
- Atherosclerosis Market to Witness Robust Expansion throughout the Forecast 2016-2026
- Biologics Contract Manufacturing Market Prophesied to Grow at a Faster Pace by 2027
- Bone Metabolism Test Market Professional Study and Research Report 2017-2027
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
